Drug Trial Radar · NCT05466318
ChiCGB vs BEAM in High-risk or R/R Lymphomas
Last checked: Nov 20, 2026Latest source record: Jul 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
306
Planned (sponsor's estimate)
Start
Jul 1, 2022
Primary completion
Dec 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Sichuan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) plays a vital role in treating high-risked or relapsed/refractory lymphoma. Our previous study showed chidamide combined with cladribine, gemcitabine, and busulfan (ChiCGB) as conditioning therapy improved the survival of these patients. So we designed this trial to verify if ChiCGB were better than BCNU, etoposide, cytarabine, and melphalan (BEAM). Patients with diffuse large B cell or extra-nodal NK/T cell Lymphoma who consent to this study will be randomized into the trial group who receive ChiCGB or the control group whom receive BEAM. Patients will be followed for up to 2 years after the hematopoietic cell transplantation (HCT).
Conditions
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, T-Cell
Interventions
ChidamideDrug
30 mg oral twice weekly for 2 weeks
CladribineDrug
6 mg/m2 intravenously once daily @ Day -7 \~ -3
GemcitabineDrug
2500 mg/m2 intravenously @ Day -7, -3
BusulfanDrug
3.2 mg/kg intravenously once daily @ Day -7 \~ -4
CarmustineDrug
300 mg/m2 intravenously @ Day -8
EtoposideDrug
200 mg/m2 intravenously once daily @ Day -7 \~ -4
CytarabineDrug
400 mg/m2 intravenously once daily @ Day -7 \~ -4
MelphalanDrug
140 mg/m2 intravenously @ Day -3
Autologous hematopoietic stem cell transplantProcedure
autologous hematopoietic stem cells infusion after ChiCGB or BEAM chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: 2 years
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
People's Hospital of Deyang City
Deyang, Deyang, China · Not yet recruiting
Chengdu Third People's Hospital
Chengdu, Sichuan, China · Not yet recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Recruiting
Chengdu First People's Hospital
Chengdu, Sichuan, China · Recruiting
PLA Western Theater Command General Hospital
Chengdu, Sichuan, China · Recruiting
Dazhou Central Hospital
Dazhou, Sichuan, China · Not yet recruiting
Southwest Medical University
Luzhou, Sichuan, China · Recruiting
Central Hospital of Mianyang City
Mianyang, Sichuan, China · Recruiting
Affiliated Hospital of North Sichuan Medical College
Nanchong, Sichuan, China · Not yet recruiting
Zigong First People's Hospital
Zigong, Sichuan, China · Recruiting
Guangyuan Central Hospital
Guangyuan, Sihcuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.